site:www.centerforbiosimilars.com

Real-World Natalizumab Biosimilar Switch Reduced Treatment Satisfaction Despite Stable Outcomes

Real-world natalizumab biosimilar switching preserved relapsing-remitting MS outcomes but lowered treatment satisfaction, ...

centerforbiosimilars

Romosozumab Biosimilar Matches Reference in Functional Testing Despite Disulfide Differences

A romosozumab biosimilar showed comparable sclerostin binding and bone-signaling potency to the reference product despite disulfide isoform differences. A romosozumab biosimilar in late-stage ...

centerforbiosimilars

Anti-VEGF Biosimilars Match Reference Drug in Indian Retinal Disease Care

Biosimilar anti-VEGF agents matched the reference ranibizumab in vision outcomes and safety across retinal diseases in India, at a lower cost. More than half of India's health care spending is paid ...

centerforbiosimilars

Rituximab Biosimilar Reached 75% Remission, Matched Innovator in Membranous Nephropathy

Real-world data shows rituximab biosimilars for membranous nephropathy match remission rates, cut costs, and expand treatment options. A lower-cost biosimilar of rituximab produced remission rates on ...